Thorsten Graef

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · New England Journal of Medicine · 2015 · 931 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Susan O’Brien, Richard R. Furman, Steven Coutré et al. · The Lancet Oncology · 2013 · 465 citations

Medicine, Immunology, Oncology +10

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Meletios Α. Dimopoulos, Alessandra Tedeschi, Judith Trotman et al. · New England Journal of Medicine · 2018 · 350 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 236 citations

Life Sciences, Immunology, Pharmacotherapy +12

KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C

Thorsten Graef, Achim K. Moesta, Paul J. Norman et al. · The Journal of Experimental Medicine · 2009 · 235 citations · Full text

Life Sciences, Immunology, Molecular Biology +16